ADTX vs. SXTC, EVFM, BLPH, NEPT, DMK, GLMD, GRI, REVB, CING, and RNAZ
Should you be buying Aditxt stock or one of its competitors? The main competitors of Aditxt include China SXT Pharmaceuticals (SXTC), Evofem Biosciences (EVFM), Bellerophon Therapeutics (BLPH), Neptune Wellness Solutions (NEPT), DMK Pharmaceuticals (DMK), Galmed Pharmaceuticals (GLMD), GRI Bio (GRI), Revelation Biosciences (REVB), Cingulate (CING), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical preparations" industry.
Aditxt (NASDAQ:ADTX) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, earnings, valuation, profitability, dividends, media sentiment and institutional ownership.
Aditxt has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500. Comparatively, China SXT Pharmaceuticals has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.
China SXT Pharmaceuticals received 78 more outperform votes than Aditxt when rated by MarketBeat users. Likewise, 61.65% of users gave China SXT Pharmaceuticals an outperform vote while only 44.44% of users gave Aditxt an outperform vote.
Aditxt presently has a consensus price target of $61.00, indicating a potential upside of 1,694.12%. Given Aditxt's higher possible upside, equities research analysts plainly believe Aditxt is more favorable than China SXT Pharmaceuticals.
China SXT Pharmaceuticals has higher revenue and earnings than Aditxt.
China SXT Pharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -3,946.13%. China SXT Pharmaceuticals' return on equity of 0.00% beat Aditxt's return on equity.
In the previous week, Aditxt had 3 more articles in the media than China SXT Pharmaceuticals. MarketBeat recorded 5 mentions for Aditxt and 2 mentions for China SXT Pharmaceuticals. China SXT Pharmaceuticals' average media sentiment score of 1.43 beat Aditxt's score of 0.34 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media.
15.5% of Aditxt shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 1.2% of Aditxt shares are owned by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
China SXT Pharmaceuticals beats Aditxt on 9 of the 15 factors compared between the two stocks.
Get Aditxt News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools